Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964438 | Vaccine | 2015 | 10 Pages |
Abstract
This study further highlights unmet needs in the influenza vaccine market, which could be addressed by the implementation of the MVA platform. Broad use of MVA in clinical trials shows great promise for this vector as vaccine platform for pre-pandemic and pandemic influenza and threats by other respiratory viruses. Moreover, from the results of the clinical trials seem that MVA is particularly attractive for development of vaccines against pathogens for which no, or only insufficiently effective vaccines, are available.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bahar Ramezanpour, Esther S. Pronker, Joost H.C.M. Kreijtz, Albert D.M.E. Osterhaus, E. Claassen,